TY - JOUR
T1 - MicroRNA therapeutics for cardiovascular disease
T2 - Opportunities and obstacles
AU - Van Rooij, Eva
AU - Olson, Eric N.
PY - 2012/11
Y1 - 2012/11
N2 - In recent years, prominent roles for microRNAs (miRNAs) have been uncovered in several cardiovascular disorders. The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors, referred to as antimiRs, has triggered enthusiasm for miRNAs as novel therapeutic targets. Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs and their relevance to cardiovascular indications, and evaluate the opportunities and obstacles associated with this new therapeutic modality.
AB - In recent years, prominent roles for microRNAs (miRNAs) have been uncovered in several cardiovascular disorders. The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors, referred to as antimiRs, has triggered enthusiasm for miRNAs as novel therapeutic targets. Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs and their relevance to cardiovascular indications, and evaluate the opportunities and obstacles associated with this new therapeutic modality.
UR - http://www.scopus.com/inward/record.url?scp=84868475728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868475728&partnerID=8YFLogxK
U2 - 10.1038/nrd3864
DO - 10.1038/nrd3864
M3 - Review article
C2 - 23080337
AN - SCOPUS:84868475728
SN - 1474-1776
VL - 11
SP - 860
EP - 872
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 11
ER -